{"id":556992,"date":"2021-08-10T18:24:01","date_gmt":"2021-08-10T18:24:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=556992"},"modified":"2021-08-10T18:24:01","modified_gmt":"2021-08-10T18:24:01","slug":"idiopathic-pulmonary-fibrosis-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/idiopathic-pulmonary-fibrosis-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments_556992.html","title":{"rendered":"Idiopathic Pulmonary Fibrosis Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1628590882.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Idiopathic Pulmonary Fibrosis Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments\" src=\"https:\/\/www.abnewswire.com\/uploads\/1628590882.png\" alt=\"Idiopathic Pulmonary Fibrosis Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s, \u201cIdiopathic Pulmonary Fibrosis &#8211; Pipeline Insight, 2021,\u201d report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Idiopathic Pulmonary Fibrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>DelveInsight&rsquo;s <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">&ldquo;Idiopathic Pulmonary Fibrosis Pipeline Insight&rdquo;<\/a> report provides comprehensive insights about key companies&nbsp;and pipeline drugs in the Idiopathic Pulmonary Fibrosis pipeline landscapes.&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">The report comprises Idiopathic Pulmonary Fibrosis pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Idiopathic Pulmonary Fibrosis therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Idiopathic Pulmonary Fibrosis pipeline products.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/60e436057e283517691727392fcf2006.jpg\" alt=\"\" \/><\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the key takeaways from the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Idiopathic Pulmonary Fibrosis Pipeline Report:<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as FibroGen, Kadmon Corporation, Promedior, Galapagos, MediciNova, etc., are developing therapies for the treatment of Idiopathic Pulmonary Fibrosis.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Emerging therapies such as <\/span><span data-mce-mark=\"1\">Pamrevlumab, KD025, PRM-151, GLPG1690, Tipelukast,<\/span><span data-mce-mark=\"1\"> are expected to have a significant impact on the <\/span><span data-mce-mark=\"1\">&nbsp;Idiopathic Pulmonary Fibrosis <\/span><span data-mce-mark=\"1\">market in the coming years.<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Get an overview of pipeline landscape @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Idiopathic Pulmonary Fibrosis Clinical Trials Analysis &nbsp;<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease characterized by the aberrant accumulation of fibrotic tissue in the lungs, associated with significant morbidity and poor prognosis. It is the most common form of fibrosing idiopathic interstitial pneumonia, is an inexorably progressive disease with a 5-year survival of ~20%.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Idiopathic Pulmonary Fibrosis Pipeline Therapies along with Key Players:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pamrevlumab by FibroGen,&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">KD025 by <\/span><span data-mce-mark=\"1\">Kadmon Corporation<\/span><span data-mce-mark=\"1\">,&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">PRM-151 by <\/span><span data-mce-mark=\"1\">Promedior,&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">GLPG1690 by <\/span><span data-mce-mark=\"1\">Galapagos,&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Tipelukast by <\/span><span data-mce-mark=\"1\">MediciNova,<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">And others.<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Scope of Idiopathic Pulmonary Fibrosis Pipeline Drug Insight&nbsp;&nbsp;&nbsp;&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Coverage: Global&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Major Players:&nbsp;<\/span><span data-mce-mark=\"1\">FibroGen, Kadmon Corporation<\/span><span data-mce-mark=\"1\">, <\/span><span data-mce-mark=\"1\">Promedior, Galapagos, MediciNova<\/span><span data-mce-mark=\"1\">, and others.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span data-mce-mark=\"1\">Pipeline Therapies:<\/span><span data-mce-mark=\"1\"> Pamrevlumab, KD025, PRM-151, GLPG1690, Tipelukast, and others.<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<div style=\"text-align: justify;\" dir=\"ltr\" align=\"left\">\n<table>\n<colgroup>\n<col width=\"22\" \/>\n<col width=\"386\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>1<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Idiopathic Pulmonary Fibrosis Report Introduction<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>2<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Idiopathic Pulmonary Fibrosis Executive Summary<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>3<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Idiopathic Pulmonary Fibrosis Overview<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>4<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Idiopathic Pulmonary Fibrosis- Analytical Perspective In-depth Commercial Assessment<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>5<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Idiopathic Pulmonary Fibrosis Pipeline Therapeutics<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>6<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Idiopathic Pulmonary Fibrosis Late Stage Products (Phase II\/III)<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>7<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Idiopathic Pulmonary Fibrosis Mid Stage Products (Phase II)<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>8<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Idiopathic Pulmonary Fibrosis Early Stage Products (Phase I)<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>9<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Idiopathic Pulmonary Fibrosis Preclinical Stage Products<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>10<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Idiopathic Pulmonary Fibrosis Therapeutics Assessment<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>11<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Idiopathic Pulmonary Fibrosis Inactive Products<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>12<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Company-University Collaborations (Licensing\/Partnering) Analysis<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>13<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Idiopathic Pulmonary Fibrosis Key Companies<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>14<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Idiopathic Pulmonary Fibrosis Key Products<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>15<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Idiopathic Pulmonary Fibrosis Unmet Needs<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>16&nbsp;<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Idiopathic Pulmonary Fibrosis Market Drivers and Barriers<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>17<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Idiopathic Pulmonary Fibrosis Future Perspectives and Conclusion<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>18<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Idiopathic Pulmonary Fibrosis Analyst Views<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>19<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Appendix<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>20<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Related Reports:<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/idiopathic-pulmonary-fibrosis-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Idiopathic Pulmonary Fibrosis Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span data-mce-mark=\"1\">DelveInsight&rsquo;s &lsquo;Idiopathic Pulmonary Fibrosis (IPF) &#8211; Market Insights, Epidemiology, and Market Forecast-2030 report deliver an in-depth understanding of the disease, historical &amp; forecasted epidemiology as well as the market trends of IPFs in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/idiopathic-pulmonary-fibrosis-epidemiology-forecast?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Idiopathic Pulmonary Fibrosis Epidemiology<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>DelveInsight&#8217;s Multiple Myeloma &#8211; Epidemiology Forecast to 2030 report delivers an in-depth understanding of the disease, historical and forecasted Multiple Myeloma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/span><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=idiopathic-pulmonary-fibrosis-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=idiopathic-pulmonary-fibrosis-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s, \u201cIdiopathic Pulmonary Fibrosis &#8211; Pipeline Insight, 2021,\u201d report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Idiopathic Pulmonary Fibrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/idiopathic-pulmonary-fibrosis-pipeline-drugs-and-companies-insight-report-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments_556992.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-556992","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/556992","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=556992"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/556992\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=556992"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=556992"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=556992"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}